Orfadin and Quinupristin and Dalfopristin
Determining the interaction of Orfadin and Quinupristin and Dalfopristin and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme. However, data evaluating the interaction are not available. MANAGEMENT: Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0 Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme. However, data evaluating the interaction are not available.
MANAGEMENT: Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
Generic Name: dalfopristin / quinupristin
Brand name: Synercid
Synonyms: Dalfopristin and quinupristin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Orfadin-Quinupristin and dalfopristin Intravenous
- Orfadin-QuinZyme coenzyme Q-10
- Orfadin-Quiphile
- Orfadin-Quit Nicotine Gum - Mint
- Orfadin-Qutenza
- Orfadin-Qvar
- Quinupristin and Dalfopristin-Orfadin (Nitisinone Capsules)
- Quinupristin and Dalfopristin-Orfadin (Nitisinone Oral Suspension)
- Quinupristin and Dalfopristin-Orfadin Suspension
- Quinupristin and Dalfopristin-Orfro
- Quinupristin and Dalfopristin-Orgaran
- Quinupristin and Dalfopristin-Orilissa